Samsung Epis Holdings삼성에피스홀딩스
0126Z0 · KOSPI · ₩0126Z0 · 삼성에피스홀딩스
₩307,000▼ ₩9,500 (3.00%)End-of-day · Oct 29, 2026 · End-of-day prices.
Filings
- Major management matter relevant to investors투자판단관련주요경영사항(자회사의 주요경영사항) (SB27(Keytruda 바이오시밀러) 미국 품목허가 신청)Oct 30, 2026Open on DART
Predicted impact: Medium
US approval filing for a Keytruda biosimilar; meaningful pipeline milestone for a large holding company.
- Preliminary earnings (consolidated)연결재무제표기준영업(잠정)실적(공정공시)Oct 28, 2026Open on DART
Predicted impact: Medium
Preliminary consolidated results from subsidiary; no figures given, so size versus last year's revenue is unknown.
- Preliminary earnings (consolidated)연결재무제표기준영업(잠정)실적(공정공시)(자회사의 주요경영사항)Oct 28, 2026Open on DART
Predicted impact: Medium
Preliminary consolidated results from subsidiary; no figures given, so size versus last year's revenue is unknown.
- Response to rumour or news report풍문또는보도에대한해명(미확정)(자회사의 주요경영사항)Oct 21, 2026Open on DART
Predicted impact: Low
- Advance Notice of Earnings Results Disclosure (Informational Disclosure)결산실적공시예고(안내공시)Oct 14, 2026Open on DART
Predicted impact: Low· Actual: +12.0% vs sector, volume 1.0× normal (5 trading days)
- Change in largest shareholder's holdings최대주주등소유주식변동신고서Oct 6, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(자회사의 주요경영사항) (중증 호산구 천식 치료제 SB41(Fasenra 바이오시밀러) 및 유전성 재발열 증후군 치료제 SB44(Ilaris 바이오시밀러) 파트너십 계약 체결)Oct 1, 2026Open on DART
- [Amendment] Disclosure of Corporate Governance Report[기재정정]기업지배구조보고서공시Sep 28, 2026Open on DART
- Change in largest shareholder's holdings최대주주등소유주식변동신고서Sep 7, 2026Open on DART
- Disclosure on Large Business Group Status [Quarterly Disclosure (For Individual Company)]대규모기업집단현황공시[분기별공시(개별회사용)]Aug 31, 2026Open on DART
- Half-year report (Jun 2026)반기보고서 (2026.06)Aug 14, 2026Open on DART
- Matters Concerning Payment Amounts by Payment Method and Payment Period, and Dispute Mediation Bodies지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항Aug 14, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(자회사의 주요경영사항) (SB27주(펨브롤리주맙 바이오시밀러) 한국 품목허가 신청)Aug 10, 2026Open on DART
- Change in largest shareholder's holdings최대주주등소유주식변동신고서Aug 4, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Aug 4, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Aug 4, 2026Open on DART
- Preliminary earnings (consolidated)연결재무제표기준영업(잠정)실적(공정공시)Jul 24, 2026Open on DART
- Preliminary earnings (consolidated)연결재무제표기준영업(잠정)실적(공정공시)(자회사의 주요경영사항)Jul 24, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(자회사의 주요경영사항) (Nectin4 단백질 표적 고형암 치료제 후보물질 SBE303 연구개발 및 상업화 계약 체결)Jul 22, 2026Open on DART
- Advance Notice of Earnings Results Disclosure (Informational Disclosure)결산실적공시예고(안내공시)Jul 10, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(자회사의 주요경영사항) (개량항체 공동기술개발 및 기술도입 옵션계약 체결)Jul 9, 2026Open on DART
- Change in largest shareholder's holdings최대주주등소유주식변동신고서Jul 6, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(자회사의 주요경영사항) (SB27(Keytruda 바이오시밀러) 제3상 임상시험 1차 유효성 분석 결과 발표)Jun 29, 2026Open on DART
- Change in largest shareholder's holdings최대주주등소유주식변동신고서Jun 8, 2026Open on DART
- Disclosure of Corporate Governance Report기업지배구조보고서공시Jun 1, 2026Open on DART
- [Corrected] Disclosure of Large Business Group Status [Annual Disclosure and Q1 Use (Individual Company)][기재정정]대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]Jun 1, 2026Open on DART
- Disclosure of Large Business Group Status [Annual Disclosure and Q1 Use (Individual Companies)]대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]Jun 1, 2026Open on DART
- Decision on Increase in Short-Term Borrowings (Material Management Matters of Subsidiary)단기차입금증가결정(자회사의 주요경영사항)May 28, 2026Open on DART
- Amended: Audit report submitted[기재정정]감사보고서제출(자회사의 주요경영사항)May 15, 2026Open on DART
- Amended: Audit report submitted[기재정정]감사보고서제출May 15, 2026Open on DART
- Quarterly report (Mar 2026)분기보고서 (2026.03)May 15, 2026Open on DART
- Amended: Annual report (Dec 2025)[기재정정]사업보고서 (2025.12)May 15, 2026Open on DART
- Change in largest shareholder's holdings최대주주등소유주식변동신고서May 11, 2026Open on DART
- Preliminary earnings (consolidated)연결재무제표기준영업(잠정)실적(공정공시)Apr 23, 2026Open on DART
- Preliminary earnings (consolidated)연결재무제표기준영업(잠정)실적(공정공시)(자회사의 주요경영사항)Apr 23, 2026Open on DART
- Advance Notice of Earnings Results Disclosure (Informational Disclosure)결산실적공시예고(안내공시)Apr 9, 2026Open on DART
- 5%+ holding report주식등의대량보유상황보고서(약식)Apr 1, 2026Open on DART
- Change in largest shareholder's holdings최대주주등소유주식변동신고서Mar 23, 2026Open on DART
- Annual general meeting results정기주주총회결과Mar 20, 2026Open on DART
- Report on Appointment, Dismissal, or Mid-Term Resignation of Independent Directors독립이사의선임ㆍ해임또는중도퇴임에관한신고Mar 20, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(자회사의 주요경영사항)Mar 18, 2026Open on DART
- Amended: Major management matter relevant to investors[기재정정]투자판단관련주요경영사항(자회사의 주요경영사항)Mar 16, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(자회사의 주요경영사항)Mar 16, 2026Open on DART
- Annual report (Dec 2025)사업보고서 (2025.12)Mar 12, 2026Open on DART
- Amended: Audit report submitted[기재정정]감사보고서제출(자회사의 주요경영사항)Mar 5, 2026Open on DART
- Audit report submitted감사보고서제출Mar 4, 2026Open on DART
- Audit report submitted감사보고서제출(자회사의 주요경영사항)Mar 4, 2026Open on DART
- Disclosure on Large Business Group Status [Quarterly Disclosure (For Individual Company)]대규모기업집단현황공시[분기별공시(개별회사용)]Mar 3, 2026Open on DART
- [Amended] Reference Document for Proxy Solicitation of Voting Rights[기재정정]의결권대리행사권유참고서류Feb 27, 2026Open on DART
- Amended: Notice of shareholders' meeting[기재정정]주주총회소집공고Feb 27, 2026Open on DART
Titles in Korean until English translations are added.
Also known as: Samsung Epis Holdings / 삼성에피스홀딩스 / 0126Z0 / KRX:0126Z0
Source: KRX statistical information